Table 3

Univariate and multivariate analysis for progression-free survival

VariablesUnivariateMultivariate
Full model 1*Full model 2†Reduced model
P valueP valueP valueHR95% CIP value
Age (years)<670.482
≥67
SexMale0.416
Female
ECOG PS0.504
00.250
10.678
≥2Ref.
IMDC risk0.3240.6220.428
Favorable0.1760.8050.967
Intermediate0.9030.4980.276
PoorRef.Ref.Ref.
HistologyClear cell0.465
Non-clear cell
Liver metastasesPresence0.901
Absence
Brain metastasesPresence0.437
Absence
Previous nephrectomyPresence0.830
Absence
No. of previous systemic therapies0.640
10.611
20.694
≥3Ref.
Baseline LDH (IU/L)<3330.155
≥333
Baseline NLR<3.00.125
≥3.0
Baseline CRP level (mg/L)<100.0780.403
≥10
Baseline CRP level (mg/L)Continuous0.0710.067
Early CRP kinetics0.0040.0080.0030.004
CRP flare-responder<0.0010.0030.0020.130.02–0.47<0.001
CRP responder0.0670.0320.0150.450.18–1.060.067
Non-CRP responderRef.Ref.Ref.Ref.
  • *Baseline CRP level was used for a categorical analysis.

  • †Baseline CRP level was evaluated as a continuous variable.

  • CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; No., number; ref., reference.